Market research
ACRS Aclaris Therapeutics Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 944M
- P/E ratio
- Not available
- Analyst target
- 10.2
- Dividend yield
- Not available
- Beta
- 0.78
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US00461U1051
- Market cap
- 944M
- P/E ratio
- Not available
- Analyst target
- 10.2
- Dividend yield
- Not available
- Beta
- 0.78
About
About Aclaris Therapeutics Inc
Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an potent and selective novel investigational dual inhibitor of ITK and JAK3 in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in Phase 1b to treat various atopic, immunologic, and respiratory diseases; ATI-9494, an oral, covalent, investigational dual inhibitor of ITK and Resting Lymphocyte Kinase (TXK), and other covalent JAK-sparing ITK inhibitors to treat modulate T cell biology across various diseases; and Lepzacitinib, a soft JAK 1/3 inhibitor for the treatment of atopic dermatitis and other dermatologic conditions. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the ACRS discussion.
5 years, 4 months ago
Aclaris Therapeutics, Inc is currently in a long term uptrend where the price is trading 14.3% above its 200 day moving average.
From a valuation standpoint, the stock is 87.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 173.9.
Aclaris Therapeutics, Inc's total revenue rose by 44.3% to $2M since the same quarter in the previous year.
Its net income has increased by 29.2% to $-13M since the same quarter in the previous year.
Finally, its free cash flow grew by 57.1% to $-9M since the same quarter in the previous year.
Based on the above factors, Aclaris Therapeutics, Inc gets an overall score of 5/5.